JP7266581B2 - 肝疾患の治療のためのアミノ酸組成物 - Google Patents

肝疾患の治療のためのアミノ酸組成物 Download PDF

Info

Publication number
JP7266581B2
JP7266581B2 JP2020508047A JP2020508047A JP7266581B2 JP 7266581 B2 JP7266581 B2 JP 7266581B2 JP 2020508047 A JP2020508047 A JP 2020508047A JP 2020508047 A JP2020508047 A JP 2020508047A JP 7266581 B2 JP7266581 B2 JP 7266581B2
Authority
JP
Japan
Prior art keywords
salt
amino acid
composition
ornithine
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020508047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530845A5 (https=
JP2020530845A (ja
JPWO2019036471A5 (https=
Inventor
コンブ，ウィリアム
キャロル，ショーン
アフェヤン，ラフィー
ハミル，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axcella Health Inc
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of JP2020530845A publication Critical patent/JP2020530845A/ja
Publication of JP2020530845A5 publication Critical patent/JP2020530845A5/ja
Publication of JPWO2019036471A5 publication Critical patent/JPWO2019036471A5/ja
Priority to JP2023003562A priority Critical patent/JP2023058496A/ja
Application granted granted Critical
Publication of JP7266581B2 publication Critical patent/JP7266581B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
JP2020508047A 2017-08-14 2018-08-14 肝疾患の治療のためのアミノ酸組成物 Active JP7266581B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023003562A JP2023058496A (ja) 2017-08-14 2023-01-13 肝疾患の治療のためのアミノ酸組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762545362P 2017-08-14 2017-08-14
US62/545,362 2017-08-14
US201862614214P 2018-01-05 2018-01-05
US62/614,214 2018-01-05
US201862697772P 2018-07-13 2018-07-13
US62/697,772 2018-07-13
PCT/US2018/046705 WO2019036471A1 (en) 2017-08-14 2018-08-14 AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023003562A Division JP2023058496A (ja) 2017-08-14 2023-01-13 肝疾患の治療のためのアミノ酸組成物

Publications (4)

Publication Number Publication Date
JP2020530845A JP2020530845A (ja) 2020-10-29
JP2020530845A5 JP2020530845A5 (https=) 2022-01-14
JPWO2019036471A5 JPWO2019036471A5 (https=) 2022-01-14
JP7266581B2 true JP7266581B2 (ja) 2023-04-28

Family

ID=63449706

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020508047A Active JP7266581B2 (ja) 2017-08-14 2018-08-14 肝疾患の治療のためのアミノ酸組成物
JP2023003562A Pending JP2023058496A (ja) 2017-08-14 2023-01-13 肝疾患の治療のためのアミノ酸組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023003562A Pending JP2023058496A (ja) 2017-08-14 2023-01-13 肝疾患の治療のためのアミノ酸組成物

Country Status (22)

Country Link
US (3) US10682325B2 (https=)
EP (1) EP3668499A1 (https=)
JP (2) JP7266581B2 (https=)
KR (1) KR20200039748A (https=)
CN (1) CN111295187A (https=)
AU (1) AU2018318112A1 (https=)
BR (1) BR112020002419A2 (https=)
CA (1) CA3070856A1 (https=)
CL (1) CL2020000382A1 (https=)
CO (1) CO2020001702A2 (https=)
CU (1) CU20200012A7 (https=)
EC (1) ECSP20011578A (https=)
IL (3) IL296055A (https=)
JO (1) JOP20200033A1 (https=)
MA (1) MA49906A (https=)
MX (1) MX2020001765A (https=)
PE (1) PE20200747A1 (https=)
PH (1) PH12020500321A1 (https=)
SG (1) SG11202001142VA (https=)
TW (1) TWI775921B (https=)
WO (1) WO2019036471A1 (https=)
ZA (1) ZA202000725B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11617731B2 (en) 2017-04-28 2023-04-04 Axcella Health, Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
IL296055A (en) 2017-08-14 2022-10-01 Axcella Health Inc Amino acid compositions for the treatment of liver disease
MA52971A (fr) * 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
CU20200106A7 (es) * 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
CN112823018A (zh) 2018-06-20 2021-05-18 胺细拉健康公司 制备氨基酸组合物的方法
US20220354817A1 (en) * 2019-09-24 2022-11-10 Myo-Tec-Sci Pharmaceutical composition for preventing or treating sarcopenia containing non-natural amino acid derivative
US20230044475A1 (en) 2019-12-23 2023-02-09 Axcella Health Inc. Compositions and methods involving amino acids for the treatment of fat infiltrations in muscle
US20230105984A1 (en) * 2019-12-23 2023-04-06 Svetlana Marukian Compositions and methods for the treatment of liver diseases and disorders
CN111602817A (zh) * 2020-05-19 2020-09-01 西安交通大学医学院第一附属医院 一种用于防治肝性肌少症的膳食组合物及其制备方法
US20230117618A1 (en) * 2021-10-19 2023-04-20 Johnson Consulting, LLC Oral Supplement to Trigger Repair Of Organs
CN119301560A (zh) * 2022-05-26 2025-01-10 吕仁硕 一种浮点数压缩方法、运算装置及计算器可读取存储媒介
WO2024204606A1 (ja) 2023-03-31 2024-10-03 フクダ電子株式会社 血圧脈波検査システム
CN119679774A (zh) * 2024-11-15 2025-03-25 北京体育大学 预防或治疗代谢性疾病的药物及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015120715A (ja) 2006-06-13 2015-07-02 株式会社明治 アミノ酸組成物を含有する疲労防止剤
CN106632605A (zh) 2016-12-22 2017-05-10 浙江海洋大学 利用金枪鱼下脚料制备的具有肝损伤修复作用的活性肽

Family Cites Families (323)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US693094A (en) 1900-08-13 1902-02-11 Hall Signal Co Signal and signaling-circuit.
US2457820A (en) 1945-12-27 1949-01-04 Merck & Co Inc Amino acid solution and process for preparing the same
GB1034358A (en) 1963-05-01 1966-06-29 Chugai Pharmaceutical Co Ltd Body-protein-biosynthesis promoting composition
US3832465A (en) 1971-12-09 1974-08-27 H Ghadimi Injectable amino acid composition commensurate to the anabolic need of the body and method of using same
US3988466A (en) 1973-06-01 1976-10-26 Kyowa Hakko Kogyo Co., Ltd. Prevention of gastric lesions
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
JPS5535049A (en) 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
DE2906034C2 (de) 1979-02-16 1985-03-28 Maggi AG, Kempttal Verfahren zur Gewinnung von L-Leucin, L-Phenylalanin, L-Tyrosin, L-Cystin und von Gemischen aus L-Leucin und L-Isoleucin
US4898879A (en) 1981-06-29 1990-02-06 Baxter International Inc. Nurtitional composition for management of hepatic failure
CA1184499A (en) 1981-06-29 1985-03-26 David C. Madsen Nutritional composition for management of hepatic failure
JPS58126767A (ja) 1982-01-22 1983-07-28 Ajinomoto Co Inc 肝臓病患者用栄養組成物
US5298493A (en) 1983-04-20 1994-03-29 Clintec Nutrition Co. Compound for use in dietetics, reanimation and therapeutics containing protein fractions based on three types of minipeptides
CH658165A5 (fr) 1984-01-04 1986-10-31 Nestle Sa Produit alimentaire efficace dans le traitement de la lepre.
US5034377A (en) 1984-11-19 1991-07-23 Montefiore Hospital Association Of Western Pennsylvania Aqueous nutrient compositions comprising oligopeptides
US4871550A (en) 1986-09-05 1989-10-03 Millman Phillip L Nutrient composition for athletes and method of making and using the same
FR2618331B1 (fr) 1987-07-23 1991-10-04 Synthelabo Compositions pharmaceutiques utiles pour le traitement de l'uremie
US5028622A (en) 1988-05-06 1991-07-02 Ajinomoto Company, Inc. Administration of amino acids as treatment for neurodegenerative disorders
US5576351A (en) 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
AU650293B2 (en) 1990-11-01 1994-06-16 Nestec S.A. High acid system nutritional formulations
US5106836A (en) 1991-02-22 1992-04-21 Clintec Nutrition Co. Enteral diet
US5977073A (en) 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
US5780039A (en) 1992-04-23 1998-07-14 Novartis Nutrition Ag Orally-ingestible nutrition compositions having improved palatability
US5229136A (en) 1992-05-21 1993-07-20 Clintec Nutrition Co. Low caloric density enteral formulation designed to reduce diarrhea in tube-fed patients
US5276018A (en) 1992-07-17 1994-01-04 Brigham And Women's Hospital Composition comprising amino acids and methods for decreasing muscle breakdown
DE4229166A1 (de) 1992-09-01 1994-03-03 Deutsches Krebsforsch Mittel zur Aufrechterhaltung und/oder Steigerung der Muskelleistung und Körperzellmasse
US5356873A (en) 1992-11-05 1994-10-18 Clintec Nutrition Co. Method for providing nutritional requirements to patients having a chronic inflammation reaction
US5348979A (en) 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
WO1994014458A1 (en) 1992-12-23 1994-07-07 Abbott Laboratories Medical foods for the nutritional support of infant/toddler metabolic diseases
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
US5891459A (en) 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5712309A (en) 1993-08-10 1998-01-27 Musashi Pty Ltd. Composition for treatment of hangovers
US5438042B1 (en) 1993-10-08 1997-08-26 Sandoz Nutrition Ltd Enteral nutritional composition having amino acid profile
AU682894B2 (en) 1993-10-28 1997-10-23 Institut National De La Recherche Agronomique Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
US5378722A (en) 1993-12-03 1995-01-03 Clintec Nutrition Co. Nutritional compositions for management of nitrogen metabolism
US5723446A (en) 1993-12-23 1998-03-03 Nestec Ltd. Enteral formulation designed for optimized nutrient absorption and wound healing
US5714472A (en) 1993-12-23 1998-02-03 Nestec Ltd. Enternal formulation designed for optimized nutrient absorption and wound healing
GB9403935D0 (en) 1994-03-01 1994-04-20 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US5719133A (en) 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
IT1275434B (it) 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
US5728678A (en) 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
JP4280310B2 (ja) 1995-08-10 2009-06-17 佐々木化学工業株式会社 アミノ酸組成剤
US5733884A (en) 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
US6087398A (en) 1996-03-01 2000-07-11 South Alabama Medical Science Foundation Sickle cell anemia treatment
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US6096785A (en) 1996-07-30 2000-08-01 Novartis Nutrition Ag Amino acid compositions and use thereof in treating renal dysfunction
JPH1053521A (ja) 1996-08-12 1998-02-24 Kagaku Gijutsu Shinko Jigyodan 脳内グルタミン酸の活性抑制剤および活性増強剤
IT1289754B1 (it) 1996-12-16 1998-10-16 Professional Dietetics Srl Composizioni a base di aminoacidi
US6013273A (en) 1997-01-27 2000-01-11 Novartis Nutrition Ag Treatment of endotoxic shock
US5817329A (en) 1997-02-28 1998-10-06 Gardiner; Paul T. Nutritional supplement for increased muscle size and strength for body builders
EP1123013A1 (en) 1997-06-02 2001-08-16 Société des Produits Nestlé S.A. Product and method for providing glutamine
US5849335A (en) 1997-06-02 1998-12-15 Nestec S.A. Composition and method for providing glutamine
DE69823739T2 (de) 1997-06-05 2005-04-28 Novartis Nutrition Ag Glycin zur Vorbeugung oder Behandlung von Transplantatabstossungen
US6281244B1 (en) 1997-06-05 2001-08-28 Novartis Nutrition Ag Therapeutic use for glycine
EP0891719A1 (en) 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
IT1294227B1 (it) 1997-08-01 1999-03-24 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l-carnitina e alcoli alifatici a lunga catena utile per la prevenzione
TW473387B (en) 1997-09-30 2002-01-21 Chugai Pharmaceutical Co Ltd Pharmaceutical or food compositions for treating hepatic diseases or improving liver functions
US6288116B1 (en) 1998-05-13 2001-09-11 Novartis Nutrition Ag Method of administration of a nutritional product to a person having renal failure
US6203820B1 (en) 1998-05-28 2001-03-20 Brice E. Vickery Compositions and methods for enhancing protein anabolism and detoxification
US6103748A (en) 1998-06-19 2000-08-15 Bryan; Thomas B. Method of treating an autoimmune disorder
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
JP2000072669A (ja) 1998-08-24 2000-03-07 Inst Of Physical & Chemical Res アミノ酸・糖組成物
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US20010041187A1 (en) 1998-10-20 2001-11-15 Carl W Hastings Performance-enhancing dietary supplement
EP1004302A3 (en) 1998-10-29 2003-06-04 Ajinomoto Co., Inc. Immunomodulator
US6051236A (en) 1998-11-12 2000-04-18 Pacifichealth Laboratories, Inc. Composition for optimizing muscle performance during exercise
US6143786A (en) 1999-02-02 2000-11-07 Novartis Nutrition Ag Oral arginine and insulin secretion
US6241996B1 (en) 1999-04-09 2001-06-05 Novartis Nutrition Ag Liquid soy nutritional products
WO2000064283A1 (en) 1999-04-27 2000-11-02 International Health Products And Services Ltd. Supplement for restoring growth hormone levels
WO2001026642A2 (en) 1999-10-08 2001-04-19 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
GB9929497D0 (en) 1999-12-14 2000-02-09 Vitaflo Limited Improved amino acid mixtures for the treatment and/or management of certain diseases
CZ20022927A3 (cs) 2000-02-01 2003-06-18 Muscletech Research And Development Inc. Doplňky stravy založené na alfa-lipoové kyselině pro zvýšení čisté svalové hmoty a síly
US6833350B2 (en) 2000-02-04 2004-12-21 Nestec S.A. Method for maintaining or improving the synthesis of mucins
US6521591B1 (en) 2000-02-10 2003-02-18 N.V. Nutricia Pharmaceutical composition for muscular anabolism
GB0009056D0 (en) 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
AU5625001A (en) 2000-04-18 2001-10-30 Societe Des Produits Nestle S.A. Nutritional modules
US6391332B1 (en) 2000-04-20 2002-05-21 Baxter International, Inc. Therapeutic micronutrient composition for severe trauma, burns and critical illness
IT1320783B1 (it) 2000-07-04 2003-12-10 Professional Dietetics Srl Composizioni a base di aminoacidi, atte al miglioramento delleprestazioni muscolari.
US20030187049A1 (en) 2000-07-04 2003-10-02 Dioguardi Francesco Saverio Compositions based on aminoacids, suitable for improving muscle performance
IT1320782B1 (it) 2000-07-04 2003-12-10 Professional Dietetics Srl Composizioni a base di aminoacidi, atte al trattamentodell'insufficienza cardiaca.
EP1372641A4 (en) 2001-03-05 2004-08-25 Stephen P Ernest ENTERAL FORMULATION
ATE441409T1 (de) * 2001-03-15 2009-09-15 Riken Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber
US20020193342A1 (en) 2001-05-09 2002-12-19 Hamman John P. Modifying undesirable tastes
ITTO20010580A1 (it) 2001-06-15 2002-12-15 Professional Dietetics Srl Composizioni a base di aminoacidi per il miglioramento della funzioneventricolare miocardica in pazienti affetti da diabete.
US6864230B2 (en) 2001-07-31 2005-03-08 Novartis Nutrition Ag Glutamine rich dietary composition
EP1466602A4 (en) 2001-12-25 2006-03-01 Ajinomoto Kk ORGAN FIBROSIS INHIBITORS
EP1471903B1 (en) 2002-01-25 2019-11-20 SciMar Ltd. Use of glutathione synthesis stimulating compounds in reducing insulin resistance
JP2003238401A (ja) 2002-02-20 2003-08-27 Ajinomoto Co Inc 疾患の治療、改善又は予防用医薬品及び飲食品
US7338675B2 (en) 2002-05-10 2008-03-04 Tsi Health Sciences, Inc. Fenugreek seed bio-active compositions and methods for extracting same
US20050176827A1 (en) 2002-05-10 2005-08-11 Lee Steve S. Compositions and methods for glycogen synthesis
US8895059B2 (en) 2002-06-05 2014-11-25 Ivax Pharmaceuticals S.R.O. Reduction of cross-linking gelatin in gelatin capsules
WO2004019928A1 (ja) 2002-08-30 2004-03-11 Ajinomoto Co., Inc. 肝疾患治療剤
US20040087490A1 (en) 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US20040057983A1 (en) 2002-09-25 2004-03-25 David Schmidt Biomolecular wearable apparatus
US7037522B2 (en) 2002-09-27 2006-05-02 Western Holdings, L.L.C. Nocturnal muscle enhancing composition and method
JP2004123564A (ja) 2002-09-30 2004-04-22 Inst Of Physical & Chemical Res 中枢機能改善用アミノ酸組成物
JP2004182705A (ja) 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
US7547450B2 (en) 2002-10-24 2009-06-16 Nestec Ltd. Senior feline food
US8093292B2 (en) 2002-11-22 2012-01-10 Bionexus, Ltd. Methods for the treatment of HIV-1 related fat maldistribution, fasting hyperlipidemia and modification of adipocyte physiology
US7288570B2 (en) 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
US20040120983A1 (en) 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
EP1582207A4 (en) 2002-12-26 2008-03-05 Ajinomoto Kk HEMMER FOR OUTBREAKING AND PROGREDIENCE OF LIVER CANCER
JP4989836B2 (ja) 2002-12-26 2012-08-01 大塚製薬株式会社 経口栄養剤
JP2006520335A (ja) 2003-03-18 2006-09-07 ノバルティス アクチエンゲゼルシャフト 脂肪酸とアミノ酸を含有する組成物
US20040213838A1 (en) 2003-04-24 2004-10-28 Mazer Terrence B. Medical food tablets containing free amino acids
JP4528925B2 (ja) 2003-05-30 2010-08-25 独立行政法人理化学研究所 アミノ酸組成物及び補液
ES2391558T3 (es) 2003-06-23 2012-11-27 Nestec S.A. Suplemento de aminoácidos para un ecosistema microbiótico sano
JP2005027524A (ja) 2003-07-08 2005-02-03 Ajinomoto Co Inc 経口アミノ酸組成物
WO2005017094A2 (en) 2003-08-19 2005-02-24 Bioadvantex Pharma Inc. N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
ITTO20030789A1 (it) 2003-10-07 2005-04-08 Professional Dietetics Srl Composizione a base di amino acidi per il trattamento
WO2005039318A1 (en) 2003-10-16 2005-05-06 Nestec S.A. Nutritional composition against side effects of chemotherapy of radiotherapy
US20050107338A1 (en) 2003-11-17 2005-05-19 Seidman Michael D. Nutritional supplement enhancing mitochondrial function
EP1685833A1 (en) 2003-11-21 2006-08-02 Ajinomoto Co., Inc. Remedy for diabetes
EP1543735B1 (en) 2003-12-20 2015-10-07 Nestec S.A. Nutritional composition for wound healing
JPWO2005072721A1 (ja) 2004-01-28 2007-09-06 味の素株式会社 局所脳血流低下に伴う神経系障害の予防または治療のための医薬組成物
CA2558220C (en) 2004-02-27 2012-01-24 Incorporated Administrative Agency National Agriculture And Food Researc H Organization Food ingredient including enriched free amino acids and their production method
US20090076111A1 (en) 2004-03-02 2009-03-19 Lee Steve S Methods for improving glycemic control in humans
US20050233013A1 (en) 2004-03-02 2005-10-20 Lee Steve S Methods for enhancing the transport of glucose for balancing blood sugar levels
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
JP4815752B2 (ja) 2004-04-01 2011-11-16 味の素株式会社 アミノ酸含有飲食品
WO2005110124A1 (en) 2004-04-15 2005-11-24 Abbott Laboratories Composition and methods for nutritional management of patients with hepatic disease
CN1582912A (zh) 2004-06-10 2005-02-23 武汉启瑞科技发展有限公司 L－鸟氨酸和 l－门冬氨酸组合物
WO2006009975A2 (en) 2004-06-22 2006-01-26 Maxim Pharmaceuticals, Inc. Histamine to treat disorders affecting muscle function
RU2372900C2 (ru) 2004-07-14 2009-11-20 Адзиномото Ко., Инк. Ингибитор возникновения и развития рака печени для применения у пациентов-людей с циррозом печени, положительных по вирусу гепатита с
JP2008506771A (ja) 2004-07-19 2008-03-06 エヌ．ブイ．・ヌートリシア 血糖値を調節するためのアスパルテートを使用するための調製物
EP1637163A1 (en) 2004-09-21 2006-03-22 Andreas Kluge Indicator of therapeutic compliance
JP5177785B2 (ja) 2004-11-02 2013-04-10 味の素株式会社 周術期患者用薬剤
SG158073A1 (en) 2004-11-26 2010-01-29 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
WO2006083381A2 (en) 2004-12-03 2006-08-10 University Of Maryland, Baltimore Composition for treating sulfur mustard toxicity and methods of using same
JPWO2006061992A1 (ja) 2004-12-10 2008-06-05 味の素株式会社 肝疾患予防・治療用組成物
US20080114067A1 (en) 2005-01-31 2008-05-15 Takanobu Yamamoto Composition for Recovery From or Prevention of Central Nervous System Fatigue
CN1679941A (zh) * 2005-02-02 2005-10-12 北京阜康仁生物制药科技有限公司 一种由牛磺酸和治疗肝病的药物组成的复方制剂及其制备方法
US20060198899A1 (en) 2005-03-01 2006-09-07 Gardiner Paul T Supplemental dietary composition for supporting muscle growth, recovery and strength
CN101175995A (zh) 2005-03-15 2008-05-07 雀巢技术公司 用于调节维生素c生物利用率的营养组合物
ES2402935T3 (es) 2005-03-21 2013-05-10 Abbott Laboratories Composición de aminoácidos para mejorar la tolerancia a la glucosa
JP5545424B2 (ja) 2005-03-29 2014-07-09 味の素株式会社 高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物
EP2243383A3 (en) 2005-04-06 2011-02-16 Nestec S.A. A method and composition for nutritionally improving glucose control and insulin action
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
US20090209647A1 (en) 2005-06-14 2009-08-20 Nestec S.A. Nutritional method
EP2184062A1 (en) 2005-06-22 2010-05-12 Ajinomoto Co., Inc. Use of glutamic acid and a nucleic acid as metabotropic glutamate receptor activators
US20100104548A1 (en) 2005-06-24 2010-04-29 Albert Einstein College Of Medicine Of Yeshiva University Modulation of amino acid metabolism in the hypothalamus
JPWO2007004613A1 (ja) 2005-07-01 2009-01-29 味の素株式会社 炎症性腸疾患治療薬及びＴＮＦ−α産生抑制剤
JP5682990B2 (ja) 2005-08-04 2015-03-11 味の素株式会社 酸化型アルブミン低下剤
WO2007018278A1 (ja) 2005-08-05 2007-02-15 Ajinomoto Co., Inc. 肝癌発生・進展抑制剤
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
EP1919304B1 (en) 2005-08-26 2011-05-25 Nestec S.A. Compositions and methods for improving functional vascular integrity, cellular survival and reducing apoptosis after an ischemic episode in the brain
EP1774973A1 (en) 2005-10-12 2007-04-18 Nutricia N.V. Leucine rich composition
CA2627566A1 (en) 2005-10-28 2007-05-10 Nestec S.A. Methods for the use of branched chain amino acids
WO2007056176A2 (en) 2005-11-03 2007-05-18 Southwest Immunology, Inc. Compositions for preventing and reducing delayed onset muscle soreness
US20070243211A1 (en) 2005-11-07 2007-10-18 Jaffe Russell M Compositions for regulating metabolic disorders and methods of use thereof
RU2414897C2 (ru) 2005-11-30 2011-03-27 Нестек С.А. Способы лечения потери мышечной массы
ES2548432T3 (es) 2005-12-19 2015-10-16 Abbott Laboratories Uso de beta-hidroxi-beta-metilbutirato para modular el desequilibrio en la producción de citoquinas de tipo 1 y tipo 2
RU2437655C2 (ru) 2006-01-09 2011-12-27 Нестек С.А. Лечение пациентов, подвергнутых стрессу
PL1983849T3 (pl) 2006-01-20 2013-09-30 Innova Food Ab Kompozycja spożywcza zawierająca aminokwasy
BRPI0706795A2 (pt) 2006-01-31 2011-04-05 Nestec Sa composição nutricional para bebês com baixo peso de nascimento
US20070270355A1 (en) 2006-05-11 2007-11-22 Garcia Ramon D Sport drink containing amino acids and carbohydrates
JP5100033B2 (ja) 2006-05-16 2012-12-19 大塚製薬株式会社 消化管及び腎臓の萎縮抑制剤
US20070286909A1 (en) 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
JP2008050277A (ja) 2006-08-22 2008-03-06 Ajinomoto Co Inc 鉄欠乏性貧血症治療用組成物
US9192593B2 (en) 2006-08-30 2015-11-24 Ajinomoto Co., Inc. Amino-acid containing composition for inhibiting accumulation of fat
MY146112A (en) 2006-10-19 2012-06-29 Nestec Sa Long-term feed - cancer patient
US20080102137A1 (en) 2006-10-31 2008-05-01 Guffey Manning V R Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
GB0624879D0 (en) 2006-12-14 2007-01-24 Shs Int Ltd Treatment of pervasive development disorders
EP1932437A1 (en) 2006-12-15 2008-06-18 Nestec S.A. Infant formula
CN100518815C (zh) 2007-02-15 2009-07-29 北京苏里曼医药科技有限公司 一种氨基酸组合物
US20080268038A1 (en) 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
CN101332209B (zh) 2007-06-25 2010-12-08 三菱制药（广州）有限公司 治疗肝性脑病的复方氨基酸注射液
US7777074B2 (en) 2007-09-18 2010-08-17 Thermolife International, Llc Amino acid compounds
US8455531B2 (en) 2007-09-18 2013-06-04 Thermolife International, Llc Amino acid compositions
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
KR100970664B1 (ko) 2007-10-11 2010-07-15 한화제약주식회사 Ｌ-오르니틴-ｌ-아스파테이트를 함유한 겔제의 제조방법 및그 겔제
CA2706656A1 (en) 2007-11-26 2009-06-04 Nestec S.A. Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition
CN101214050B (zh) 2007-12-28 2011-08-31 叶高山 一种具有提神、抗疲劳、醒酒功能的保健饮料
CA2994586C (en) 2008-01-04 2020-07-21 Nestec S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
US7790688B2 (en) 2008-01-11 2010-09-07 Healthspan Solutions, Llc Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly
US20090186098A1 (en) 2008-01-18 2009-07-23 Jose Briceno Sports drink composition
ATE523095T1 (de) 2008-01-25 2011-09-15 Cesar Gallia S R L Aminosäurenkonzentrat in wässrigem gel und mittels verdünnung besagten konzentrats mit wasser erhaltenes getränk zur bekämpfung von müdigkeit
US8716249B2 (en) 2008-01-31 2014-05-06 Energy Light Llc Compositions and methods for improving cardiovascular health
WO2009100241A2 (en) 2008-02-05 2009-08-13 Healthspan Solutions, Llc Systems for and methods of use of therapeutic nutrition for the management of age-associated and age-specific health conditions of the elderly.
AU2009210728B2 (en) 2008-02-07 2014-06-19 Société des Produits Nestlé S.A. Compositions and methods for influencing recovery from strenuous physical activity
EP2098126A1 (en) 2008-03-03 2009-09-09 Nestec S.A. Carbohydrate Bar
EP2098124A1 (en) 2008-03-03 2009-09-09 Nestec S.A. Carbohydrate gel
CN102316730A (zh) 2008-05-09 2012-01-11 天雅瑞药业有限公司 用于减轻全身性炎症和/或血管炎症的n-乙酰半胱氨酸(nac)的控释
US20090306209A1 (en) 2008-06-04 2009-12-10 Daugherty F Joseph Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
US20100021573A1 (en) 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
EP3011843A1 (en) 2008-09-19 2016-04-27 Nestec S.A. Nutritional support of the immune system during anti-cancer treatment
EP2165713B1 (en) 2008-09-19 2012-11-14 Nestec S.A. Whey and thymus function
WO2010050168A1 (ja) 2008-10-27 2010-05-06 味の素株式会社 バリン、イソロイシン、ロイシン固溶体およびその製造方法
US8362080B2 (en) 2008-12-18 2013-01-29 Baylor College Of Medicine Increasing glutathione levels for therapy
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US20120178672A1 (en) 2009-03-18 2012-07-12 Wolfe Robert R Compositions and Methods for Sparing Muscle in Renal Insufficiency and During Hemodialysis
WO2010108542A1 (en) 2009-03-25 2010-09-30 Nestec S.A. A natural taste enhancing savoury base and a process for its preparation
CA2757373C (en) 2009-04-03 2018-05-08 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
WO2010126353A1 (en) 2009-04-27 2010-11-04 N.V. Nutricia Pea-based protein mixture and use thereof in a liquid nutritional composition suitable for enteral feeding
US8703719B1 (en) 2009-05-18 2014-04-22 Bio-Engineered Supplements And Nutrition, Inc. Method and composition for improved muscle performance
EA201691430A1 (ru) 2009-06-08 2017-02-28 ЮСиЭл БИЗНЕС ПиЭлСи Лечение портальной гипертензии и восстановление функции печени с помощью l-орнитинфенилацетата
WO2010143939A1 (en) 2009-06-09 2010-12-16 N.V. Nutricia Nutrition for improving muscle strength in elderly
JP2012533627A (ja) 2009-07-20 2012-12-27 ネステク ソシエテ アノニム 機能状態の喪失を減弱する方法
WO2011030104A1 (en) 2009-09-09 2011-03-17 Rajiv Jalan Phenylacetate and/or phenylbutyrate (not ornithine) for reducing portal blood pressure
CN101664384B (zh) 2009-09-18 2011-09-14 杭州市第六人民医院 N-乙酰半胱氨酸盐木糖醇注射液及其制备方法和应用
WO2011044230A2 (en) 2009-10-06 2011-04-14 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions
WO2011043647A1 (en) 2009-10-09 2011-04-14 N.V. Nutricia Amino acid composition with improved dispersibility
EP2327316B1 (en) 2009-11-29 2016-11-16 Premier Nutrition Corporation Method of enhancing muscle protein synthesis
EP2327315B1 (en) 2009-11-29 2013-10-09 Nestec S.A. Dosing protocols for increasing protein synthesis in an active individual
WO2011078654A1 (en) 2009-12-24 2011-06-30 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
JP2011132174A (ja) 2009-12-24 2011-07-07 Kirin Holdings Co Ltd 持久力向上剤
WO2011097273A1 (en) 2010-02-02 2011-08-11 Martek Biosciences Corporation Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl lcystenine
CA2792396C (en) 2010-03-12 2018-09-11 Nestec S.A. Compositions for masking the flavor of nutrients and methods for making same
WO2011119023A1 (en) 2010-03-26 2011-09-29 N.V. Nutricia Low protein infant formula with increased essential amino acids
US20130210715A1 (en) 2010-04-26 2013-08-15 Nestec S.A. Nutritional compositions and methods for weaning from parenteral nutrition to enteral nutrition
US8840950B2 (en) 2010-05-26 2014-09-23 Jacqueline M. Hibbert Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
KR101213825B1 (ko) 2010-07-16 2012-12-18 서울대학교산학협력단 세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물
MY173215A (en) 2010-07-21 2020-01-06 Cumberland Pharmaceuticals Inc Acetylcysteine compositions and methods of use thereof
US20120020947A1 (en) 2010-07-22 2012-01-26 Northern Innovations And Formulations Corp. Compositions and methods for increasing lean muscle mass after exercise
CN101912394B (zh) * 2010-08-06 2013-11-06 岳茂兴 一种用于治疗凝血障碍出血的药物组合物及其用途
MX360062B (es) 2010-10-06 2018-10-22 Ocera Therapeutics Inc Metodos de elaboracion de fenilacetato de l-ornitina.
EP2444083A1 (en) 2010-10-21 2012-04-25 Nestec S.A. Cysteine and food intake
SG191315A1 (en) 2010-12-22 2013-07-31 Abbott Lab Nutritional products comprising calcium beta-hydroxy-beta methylbutyrate and conjugated linoleic acid
CA2821312A1 (en) 2010-12-27 2012-07-05 Abbott Laboratories Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate
WO2012097061A1 (en) 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for improving skeletal muscle protein metabolism
RU2597793C2 (ru) 2011-01-25 2016-09-20 Нестек С.А. Способы и композиции для лечения, ослабления или предотвращения ухудшения зрительной системы животных
RU2491062C2 (ru) 2011-03-16 2013-08-27 Общество С Ограниченной Ответственностью "Биотехнологии Пущино" Композиции протекторов острых и хронических печеночных энцелопатий и способ лечения острых и хронических печеночных энцелопатий
JP2014515011A (ja) 2011-03-18 2014-06-26 ネステク ソシエテ アノニム 加齢に伴う疾病を改善するのに有用な組成物及び方法
CN102327259A (zh) 2011-03-31 2012-01-25 姜国辉 具有显著化学性肝损伤保护功能的复合生物制剂
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
EP2696868A1 (en) 2011-04-12 2014-02-19 Nestec S.A. Nutritional compositions including branched chain fatty acids and methods of using same
CN103491804A (zh) 2011-04-18 2014-01-01 雀巢产品技术援助有限公司 具有α-HICA 和二十碳五烯酸的营养组合物
US20120270860A1 (en) 2011-04-19 2012-10-25 Gihyun Yoon Methods for treating or preventing alcohol-related disorders or craving-related disorders
JP2014513527A (ja) 2011-04-21 2014-06-05 ネステク ソシエテ アノニム パフォーマンス向上のための栄養組成物並びにその作製及び使用方法
US8828426B2 (en) 2011-06-07 2014-09-09 Zx Pharma, Llc Multiparticulate L-carnitine compositions and related methods
US20130090356A1 (en) 2011-06-24 2013-04-11 Jon D. Kaiser Compositions and methods for treatment of neuropsychological deficits
US20140135396A1 (en) 2011-07-05 2014-05-15 Beth Israel Deaconess Medical Center, Inc. Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide
BR112014002779A2 (pt) 2011-08-08 2017-02-21 Ajinomoto Kk composição contendo aminoácido para o melhoramento da recuperação a partir de fadiga muscular
HK1199378A1 (en) 2011-08-19 2015-07-03 Musclepharm Corporation Compositions and methods for use in promoting lean body mass
EP2574333B1 (en) 2011-09-27 2017-01-11 Friulchem SpA N-acetylcysteine effervescent tablet and its therapeutical applications
EP2580967A1 (en) 2011-10-11 2013-04-17 Nestec S.A. Accelerating muscle recovery after immobilization-induced muscle atrophy
EP2583565A1 (en) 2011-10-21 2013-04-24 Nestec S.A. Use of whey protein micelles for enhancing energy expenditure and satiety
EP2583563A1 (en) 2011-10-21 2013-04-24 Nestec S.A. Whey protein micelles against muscle atrophy and sarcopenia
US9364463B2 (en) 2011-11-18 2016-06-14 Board Of Trustees Of The University Of Arkansas Use of amino acid supplementation for improved muscle recovery
CN108478551A (zh) 2011-11-21 2018-09-04 埃默斯医疗股份有限公司 用于治疗糖尿病和相关病症的方法和组合物
WO2013081154A1 (ja) 2011-12-02 2013-06-06 味の素株式会社 キナーゼ阻害剤の副作用低減剤
AU2013210373A1 (en) 2012-01-19 2014-09-04 Shoichi Shirotake Antibacterial agent against plant disease-causing bacteria
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
WO2013188258A1 (en) 2012-06-11 2013-12-19 Abbott Laboratories Use of hmb to improve health outcomes for hospitalized patients
JP6368306B2 (ja) 2012-07-31 2018-08-01 ネステク ソシエテ アノニム 炎症性腸疾患（ｉｂｄ）患者の筋骨格の健康を促進させるための栄養組成物
CA2884717A1 (en) 2012-09-14 2014-03-20 Nestec S.A. Novel flavour compositions with improved flavour and/or flavour shelf-life
US9198889B2 (en) 2012-09-19 2015-12-01 Quality IP Holdings, LLC Methods for treating post-traumatic stress disorder
US8747921B2 (en) 2012-09-19 2014-06-10 Quality Ip Holdings, Inc. Methods for improving health in humans
US9066953B2 (en) 2012-09-20 2015-06-30 Quality IP Holdings, LLC Methods for increasing endurance and fat metabolism in humans
CN102961377A (zh) 2012-11-08 2013-03-13 湖北一半天制药有限公司 复方氨基酸注射液（20aa）的制备方法
ES2633769T3 (es) 2012-12-04 2017-09-25 Nestec S.A. Hexanoilglicina como biomarcador para la predisposición al aumento de peso y a la obesidad
CA2899925A1 (en) 2013-02-04 2014-08-07 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
KR101969199B1 (ko) 2013-03-11 2019-04-15 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 폐 기능의 개선 및 방사선 유발된 폐 합병증의 예방 및/또는 치료를 위한 물질 및 방법
CN105228627B (zh) 2013-03-15 2018-07-13 纽斯尔特科学公司 亮氨酸和烟酸降低脂质水平
CN105246357A (zh) 2013-03-26 2016-01-13 普瑞米尔营养公司 提高组合训练后肌肉蛋白质合成的方法
ES2617714T5 (es) 2013-04-15 2021-02-11 Nestle Sa Empleo de la proteína de suero en combinación con la estimulación eléctrica muscular
ES2844199T3 (es) 2013-04-16 2021-07-21 Childrens Hospital Philadelphia Composiciones y métodos para el tratamiento de lesiones cerebrales
WO2014191856A1 (en) 2013-05-31 2014-12-04 Nestec S.A. Methods for enhancement of muscle protein synthesis
EP3019024B1 (en) 2013-06-28 2017-02-01 Nestec S.A. Compositions and methods for enhancing exercise performance
WO2015015149A1 (en) 2013-07-31 2015-02-05 Leeds Metropolitan University Dietary supplement
EP3048904A2 (en) 2013-09-25 2016-08-03 Pronutria Biosciences, Inc. Compositions and formulations for treatment of gastrointestinal tract malabsorption diseases and inflammatory conditions and methods of production and use thereof
US20180125926A1 (en) 2013-09-25 2018-05-10 Axcella Health Inc. Compositions and Formulations and Methods of Production and Use Thereof
EP3054938A1 (en) 2013-10-09 2016-08-17 Nestec S.A. Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome
WO2015061607A1 (en) 2013-10-23 2015-04-30 Whitehead Institute For Biomedical Research Mtorc1 modulation by amino acids and uses thereof
EP3110507B1 (en) 2014-02-27 2020-11-18 NuSirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
GB2523578A (en) 2014-02-28 2015-09-02 Daniel Nelson A nutritional supplement
WO2015161448A1 (en) 2014-04-22 2015-10-29 Wuhan Ll Science And Technology Development Co., Ltd. Ornithine-containing or aspartate-containing compositions and the uses thereof
CN105092753B (zh) 2014-05-20 2016-09-07 中国科学院大连化学物理研究所 组合型胺类代谢标志物的应用及试剂盒
WO2016003263A1 (en) 2014-07-01 2016-01-07 N.V. Nutricia Amino acid based diet with improved taste
US10217645B2 (en) 2014-07-25 2019-02-26 Versum Materials Us, Llc Chemical mechanical polishing (CMP) of cobalt-containing substrate
CN105360846A (zh) * 2014-08-19 2016-03-02 武汉宏博生物技术有限公司 一种氨基酸饮料
US20160158305A1 (en) 2014-09-19 2016-06-09 Chip E. Thomson Additives and supplements
WO2016058919A1 (en) 2014-10-14 2016-04-21 Nestec S.A. Improvement in muscle functionality of elderly males
US10039735B2 (en) 2014-11-24 2018-08-07 Ucl Business Plc Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
UA120627C2 (uk) 2014-12-04 2020-01-10 Профешенал Дайатетікс С.П.А. Композиція на основі амінокислоти для відновлення фіброеластину в дермальній сполучній тканині
US10894024B2 (en) 2014-12-08 2021-01-19 Synaptamine, Inc. Anti-RDS compounds and method of manufacture and administration thereof to induce dopamine homeostatis
EP3034074A1 (en) 2014-12-18 2016-06-22 Universitat De València, Estudi General Compound for treatment of myotonic dystrophy type 1
JP6959136B2 (ja) 2015-01-23 2021-11-02 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 患者の示差的な栄養所要量の決定方法
US20170368026A1 (en) 2015-01-23 2017-12-28 Nestec S.A. Promotion of healing of intestinal mucosa using proline, serine and threonine
AU2016208455A1 (en) 2015-01-23 2017-06-15 Société des Produits Nestlé S.A. Nutritional composition useful in the treatment of IBD patients
US20180021278A1 (en) 2015-01-23 2018-01-25 Nestec S.A. Treatment or prevention of inflammation using serine
JP6847668B2 (ja) 2015-01-27 2021-03-24 昇一 城武 ナノ粒子を有効成分とする皮膚炎の治療又は予防剤
US20180036270A1 (en) 2015-02-13 2018-02-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College A method of protecting against carbonyl stress induced ischemia-reperfusion injury in the diabetic brain via administration of n-acetylcysteine
BR112017014924A2 (pt) 2015-02-13 2018-03-20 Nestec Sa Tratamento ou prevenção de caquexia induzida por cirurgia e/ou expressão de células supressoras de origem mieloide e citoquinas pró- inflamatórias
FR3032883B1 (fr) 2015-02-24 2017-03-17 International Nutrition Res Company Composition pour la prevention et le traitement de la steatose et de la steatohepatite metaboliques
US20160302451A1 (en) 2015-04-16 2016-10-20 Michael Hudnall Medical Food for Patients with Chronic Liver Disease
RU2755904C2 (ru) 2015-04-20 2021-09-22 Осера Терапьютикс, Инк. Составы l-орнитин фенилацетата
US10123985B2 (en) 2015-06-08 2018-11-13 Whitehead Institute For Biomedical Research Therapeutic strategies for treating mitochondrial disorders
ES2860427T3 (es) 2015-06-22 2021-10-05 Nestle Sa Composiciones y métodos para mejorar la neurogénesis en animales
MX380541B (es) 2015-06-30 2025-03-12 Soc Des Produits Nestle S A Star Composición adecuada para proteger microorganismos.
RU2755478C2 (ru) 2015-07-15 2021-09-16 Юниджен, Инк. Композиции, способы и медицинские композиции для лечения и поддержания здоровья печени
ES2875601T3 (es) 2015-08-14 2021-11-10 Nestle Sa Composiciones alimentarias semihúmedas que mantienen una textura blanda
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
US11019817B2 (en) 2015-08-25 2021-06-01 Shoichi Shirotake Antimicrobial agent against germs which has excellent plant disease control effect
US20170079897A1 (en) 2015-09-20 2017-03-23 Matthew Brissette MINUS Composition for hair application and methods of hair care
AU2016325556B2 (en) 2015-09-25 2023-02-16 Ocera Therapeutics, Inc. Treatment and prevention of neuronal cell loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US20170196944A1 (en) 2015-09-28 2017-07-13 Robert Portman Method to reduce muscle atrophy following orthopedic surgery
AU2016353350B2 (en) 2015-11-13 2021-09-23 Ocera Therapeutics, Inc. Formulation of L-ornithine phenylacetate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
CA3001091A1 (en) 2015-11-20 2017-05-26 Nestec S.A. Methods using whey protein to improve or maintain muscle quality
GB2561747B (en) 2015-12-21 2021-05-12 Nanjing Jianrong Bio Tech Co Ltd Composition for treating motor neuron diseases and use thereof
EA201891592A1 (ru) 2016-01-08 2019-02-28 КОЛОНАРИКОНСЕПТС ЭлЭлСи Основанная на пищевых продуктах доставка терапевтического агента для лечения печеночной энцефалопатии
GB201600990D0 (en) 2016-01-19 2016-03-02 Abbott Lab Pharmaceutical or nutritional combination
US20190133147A1 (en) 2016-05-11 2019-05-09 Tsubo Solutions Pty Ltd Confectionery product
JP2019518744A (ja) 2016-05-27 2019-07-04 ネステク ソシエテ アノニム 運動障害を治療又は予防するための栄養組成物
PL238958B1 (pl) 2016-06-29 2021-10-25 Olimp Laboratories Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja aminokwasowa do stosowania przed wysiłkiem fizycznym
US20180015122A1 (en) 2016-07-14 2018-01-18 Companion Supplements, LLC Pharmaceutical composition effective in preventing adverse effects associated with the use of glucocorticoids
US11033522B2 (en) 2016-08-09 2021-06-15 David C Scott Free amino acid preparation and uses thereof
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JOP20190147A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض واضطرابات العضلات
SE540582C2 (en) 2016-12-22 2018-10-02 Scandibio Therapeutics Ab Substances for treatment of fatty liver-related conditions
KR20190119046A (ko) 2017-01-19 2019-10-21 오톨로직 파마슈틱스, 인크. N-아세틸시스테인의 제제 및 이의 용도
US11617731B2 (en) 2017-04-28 2023-04-04 Axcella Health, Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
CN107242552A (zh) 2017-07-07 2017-10-13 上海东锦食品集团有限公司 具有缓解体力疲劳及增强免疫力功能的保健食品组合物
WO2019036442A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF NEURONAL INJURY
IL296055A (en) 2017-08-14 2022-10-01 Axcella Health Inc Amino acid compositions for the treatment of liver disease
CN108041501A (zh) 2017-12-22 2018-05-18 北京康比特体育科技股份有限公司 一种促进疲劳恢复的蛋白组合物及其制备方法
JOP20200324A1 (ar) 2018-06-20 2020-12-14 Axcella Health Inc تركيبات للعلاج والصحة تحتوي على أحماض أمينية ذات طعم مُر
WO2019246221A1 (en) 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
CN112823018A (zh) 2018-06-20 2021-05-18 胺细拉健康公司 制备氨基酸组合物的方法
CN108524453A (zh) 2018-07-05 2018-09-14 扬子江药业集团广州海瑞药业有限公司 一种门冬氨酸鸟氨酸的药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015120715A (ja) 2006-06-13 2015-07-02 株式会社明治 アミノ酸組成物を含有する疲労防止剤
CN106632605A (zh) 2016-12-22 2017-05-10 浙江海洋大学 利用金枪鱼下脚料制备的具有肝损伤修复作用的活性肽

Also Published As

Publication number Publication date
TWI775921B (zh) 2022-09-01
US20200306214A1 (en) 2020-10-01
US20190247351A1 (en) 2019-08-15
JP2023058496A (ja) 2023-04-25
US10660870B2 (en) 2020-05-26
CU20200012A7 (es) 2021-02-04
BR112020002419A2 (pt) 2020-07-28
WO2019036471A9 (en) 2020-01-30
AU2018318112A1 (en) 2020-02-13
JP2020530845A (ja) 2020-10-29
IL286592B (en) 2022-10-01
CO2020001702A2 (es) 2020-05-29
US20190046487A1 (en) 2019-02-14
WO2019036471A1 (en) 2019-02-21
CL2020000382A1 (es) 2020-08-28
MA49906A (fr) 2020-06-24
IL286592B2 (en) 2023-02-01
IL286592A (en) 2021-10-31
IL272309A (en) 2020-03-31
CA3070856A1 (en) 2019-02-21
US11571404B2 (en) 2023-02-07
SG11202001142VA (en) 2020-03-30
EP3668499A1 (en) 2020-06-24
PH12020500321A1 (en) 2021-01-04
TW201919601A (zh) 2019-06-01
IL296055A (en) 2022-10-01
KR20200039748A (ko) 2020-04-16
US10682325B2 (en) 2020-06-16
IL272309B (en) 2021-10-31
PE20200747A1 (es) 2020-07-24
ECSP20011578A (es) 2020-04-22
JOP20200033A1 (ar) 2020-02-13
CN111295187A (zh) 2020-06-16
MX2020001765A (es) 2020-07-29
ZA202000725B (en) 2021-08-25

Similar Documents

Publication Publication Date Title
JP7266581B2 (ja) 肝疾患の治療のためのアミノ酸組成物
TWI780096B (zh) 胺基酸組合物及肌肉疾病與病症之治療方法
JP2023145496A (ja) 神経細胞損傷の治療のためのアミノ酸組成物
US11058654B2 (en) Compositions and methods for the treatment of hemoglobinopathies and thalassemias
WO2019246221A1 (en) Compositions and methods for the treatment of liver diseases and disorders
JP2018537987A (ja) 哺乳動物において筋タンパク質合成および／または機能強度を増大させる方法および組成物ならびに組成物を製造する方法
EP4081205A1 (en) Compositions and methods involving amino acids for the treatment of fat infiltrations in muscle
US20230105984A1 (en) Compositions and methods for the treatment of liver diseases and disorders
US20230000808A1 (en) Compositions and methods excluding or with reduced glutamine for the treatment of hemoglobinopathies and thalassemias
OA20063A (en) Amino acid compositions for the treatment of liver disease.
CA3106895A1 (en) Nutritional compositions for enhancement of muscle performance

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211228

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20211228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220808

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230113

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230113

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230131

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230228

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230411

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230418

R150 Certificate of patent or registration of utility model

Ref document number: 7266581

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150